Table 1.
Frequency of primary resistance (disease progression as best response) in selected studies of immune checkpoint inhibitors with or without chemotherapy.
| Study | Treatment | ORR (%) | PD as best response (%) | |
|---|---|---|---|---|
| First line setting | ||||
| Monotherapy | KN02415 | Pembrolizumab | 44.8 | 22 |
| KN04216 | Pembrolizumab (TPS ⩾1%) | 27.3 | 21 | |
| CM02617 | Nivolumab | 26 | 27 | |
| Chemotherapy + ICI | KN18918 | Chemotherapy + Pembrolizumab | 47.6 | 8.8 |
| KN40719 | Chemotherapy + Pembrolizumab | 58.4 | 6.9 | |
| IMpower13020 | Chemotherapy + Atezolizumab | 49.2 | 11 | |
| IMpower13121 | Chemotherapy + Atezolizumab | 49 | Not reported | |
| IMpower15022 | Chemotherapy + Bevacizumab + Atezolizumab | 63.5 | 18 | |
| ICI + ICI | CM22723 | Ipilimumab + Nivolumab (TMB high) | 45.3 | 15.8 |
| MYSTIC24 | Durvalumab + Tremelimumab | 34.4 | Not reported | |
| Pre-treated setting | ||||
| Monotherapy | CM01725 | Nivolumab | 20 | 41 |
| CM05726 | Nivolumab | 19 | 44 | |
| KN01027 | Pembrolizumab (TPS ⩾1%) | 18 | 20–25 | |
| OAK28 | Atezolizumab | 14 | 44 | |
CM, CHECKMATE; ICI, immune checkpoint inhibitor; KN, KEYNOTE; ORR, overall response rate; PD, progressive disease; TPS, tumor proportion score.